Ignite Creation Date:
2024-05-05 @ 9:59 PM
Last Modification Date:
2024-10-26 @ 10:12 AM
Study NCT ID:
NCT01006265
Status:
COMPLETED
Last Update Posted:
2022-02-07
First Post:
2009-10-30
Brief Title:
Clinical Study to Evaluate the Efficacy Safety and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Multicenter Randomized Double-blind Placebo-controlled Parallel-group Dose-finding Study to Evaluate the Efficacy Safety and Tolerability of Three Doses of ACT-128800 an Oral S1P1 Receptor Agonist Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the efficacy safety and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None